Omalizumab (Subcutaneous Route)

Name: Omalizumab (Subcutaneous Route)

US Brand Name

  1. Xolair

Pediatric

Use of omalizumab injection to treat asthma in children younger than 6 years of age and CIU in children younger than 12 years of age is not recommended. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of omalizumab injection in the elderly.

(web3)